Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) will release fourth quarter and full year 2025 financial results and operational highlights before U.S. market open on March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss results and provide a business update.

Participants must pre-register to receive dial-in numbers and a personal PIN. A simultaneous audio webcast and replay will be available on the company events website.

Key Figures

Earnings release date: March 27, 2026 Conference call time EDT: 8:30am EDT Conference call time GMT: 12:30pm GMT

3 metrics

Earnings release date March 27, 2026 Fourth quarter and full year 2025 results release before U.S. market open

Conference call time EDT 8:30am EDT Management call to discuss 2025 financial results and business update

Conference call time GMT 12:30pm GMT Simultaneous webcast for international investors

Market Reality Check

Price: $1.51 Vol: Volume 445,554 is 0.26x t...

low vol

$1.51 Last Close

Volume Volume 445,554 is 0.26x the 20-day average 1,699,482, indicating muted trading interest pre-announcement. low

Technical Shares at $1.44 are trading below the 200-day moving average of $1.74 and 46.67% under the 52-week high.

Peers on Argus

AUTL was up 3.47% while key biotech peers were generally weaker: ADCT -0.96%, BN...

AUTL was up 3.47% while key biotech peers were generally weaker: ADCT -0.96%, BNTC -0.93%, CGEM -3.85%, AURA -1.0%, with only YMAB +0.23%. This points to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Investor conferences	Neutral	+5.2%	Announcement of participation in March 2026 investor conferences and webcasts.
Feb 04	Inducement grants	Neutral	+0.0%	Inducement stock options granted under Nasdaq Listing Rule 5635(c)(4).
Jan 12	Prelim 2025 revenue	Positive	-17.1%	Preliminary AUCATZYL 2025 revenue, 2026 guidance and positive margin/cash outlook.
Jan 06	Manufacturing automation	Positive	+7.5%	Evaluation of Cellares Cell Shuttle platform to enhance CAR-T manufacturing capacity.
Dec 08	Lupus trial update	Positive	-6.3%	Updated Phase 1 CARLYSLE data for obe-cel in severe refractory systemic lupus.

Pattern Detected

The stock has shown divergence on some fundamentally positive updates, selling off after strong revenue and lupus data while reacting positively to manufacturing and conference news.

Recent Company History

Over the last six months, Autolus has moved from early commercial metrics to broader strategic and clinical updates. Preliminary 2025 revenue and 2026 guidance on Jan 12, 2026 triggered a -17.13% move despite positive fundamentals, while manufacturing automation news on Jan 6, 2026 saw a +7.53% reaction. Updated lupus data on Dec 8, 2025 led to a -6.29% move. More routine items like inducement grants and conference participation had modest to positive or flat impacts. Today’s earnings-date announcement fits the pattern of scheduling/housekeeping news ahead of fuller financial details.

Market Pulse Summary

This announcement sets the timetable for Autolus’s fourth quarter and full year 2025 results, with a...

Analysis

This announcement sets the timetable for Autolus’s fourth quarter and full year 2025 results, with a conference call on March 27, 2026 to discuss financials and a business update. Investors can frame this alongside recent milestones such as preliminary 2025 revenue, 2026 guidance, and clinical and manufacturing developments. Key items to watch in the upcoming release include commercial traction for AUCATZYL, updated guidance versus prior figures, and any changes to cash runway or strategic priorities.

Key Terms

t cell therapies

1 terms

t cell therapies medical

"developing, manufacturing and delivering next-generation programmed T cell therapies"

T cell therapies are treatments that use a patient’s own infection-fighting cells, or lab-modified versions of them, to seek out and destroy diseased cells such as cancer. Think of it as retraining and equipping a person’s internal soldiers to recognize and attack a specific target; for investors, these therapies represent high potential returns because they can be highly effective but also carry big scientific, manufacturing and regulatory risks that affect commercial success.

AI-generated analysis. Not financial advice.

LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results and operational highlights before open of U.S. markets on Friday, March 27, 2026.

Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL^®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Amanda Cray 
+1 617-967-0207 
a.cray@autolus.com 

FAQ

When will Autolus (AUTL) release Q4 and full year 2025 financial results?

Autolus will release Q4 and full year 2025 results before U.S. market open on March 27, 2026. According to Autolus, the announcement includes operational highlights and will precede a management conference call and webcast at 8:30am EDT / 12:30pm GMT.

What time is the Autolus (AUTL) earnings conference call on March 27, 2026?

The conference call is scheduled for 8:30am EDT / 12:30pm GMT on March 27, 2026. According to Autolus, management will discuss the company's financial results and provide a general business update during the webcast and replay.

How can investors access Autolus (AUTL) conference call and webcast on March 27?

Investors should pre-register to receive dial-in numbers and a personal PIN required to join the conference call. According to Autolus, a simultaneous audio webcast and replay will be accessible on the events section of the company's website for listeners.

Will Autolus (AUTL) provide a replay of the March 27, 2026 webcast?

Yes. A simultaneous audio webcast and replay will be available on the company's events webpage. According to Autolus, the replay allows investors who cannot join live to listen to the management discussion and Q&A after the call.

What will Autolus (AUTL) cover during the March 27, 2026 call?

Management will discuss fourth quarter and full year 2025 financial results and provide a general business update. According to Autolus, the call will cover operational highlights and allow for investor questions via the conference format.

Does Autolus (AUTL) require registration to participate in the March 27 earnings call?

Yes, pre-registration is required to receive the dial-in numbers and a personal PIN needed to access the call. According to Autolus, registering ahead of time ensures participants receive the login details and phone access information.